FindTrial
Sign In

Effect of a calming medication on reducing anxiety before wisdom tooth removal

Effectiveness of sublingual alprazolam in reducing anxiety in impacted third molar surgery - controlled clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-6bzfrn
Enrollment
Unknown
Registered
2020-08-26
Start date
2019-09-02
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Impacted teeth/ Dental Anxiety

Interventions

150 patients with indication for removal of third mandibular molars were recruited for this research. In group I, the 50 patients received 0.5 mg of sublingual alprazolam as an anxiolytic medication.
Drug
Procedure/surgery
E06.892

Sponsors

Hospital Universitário da Universidade Federal de Sergipe
Lead Sponsor
Hospital Universitário da Universidade Federal de Sergipe
Collaborator

Eligibility

Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients over 18 years; Systemically healthy patients;Presence of asymptomatic impacted third molars; third molars classified as IIB by Pell and Gregory Classification.

Exclusion criteria

Exclusion criteria: Pregnancy or lactation; History of Allergies to drugs or substances used in this experiment; Patients on therapeutic use of psychiatric drugs; menstrual period women.

Design outcomes

Primary

MeasureTime frame
Expected primary outcome: Sublingual Alprazolam is effective in controlling anxiety in oral surgery, having previously checked the surgery using the Corah Anxiety Scale and In the post-surgical period through a questionnaire that expresses the patient's experience when undergoing the surgical procedure.;Primary outcome obtained: Sublingual Alprazolam obtained results similar to midazolam and better than placebo in controlling anxiety by controlling subjective patient assessment.—

Secondary

MeasureTime frame
Expected Secondary Outcome 1: Reduction of systolic blood pressure by 20mmHg during the surgical procedure in the sublingual Alprazolam group.;Secondary outcome obtained 1: maintenance of systolic blood pressure during the surgical procedure in the sublingual Alprazolam group.;Expected Secondary Outcome 2: Reduced heart rate during the surgical procedure in the sublingual Alprazolam group.;Secondary outcome obtained 2: maintenance of heart rate during the surgical procedure in the sublingual Alprazolam group.—

Countries

Brazil

Contacts

Public ContactHélio Igor Albuquerque

Hospital Universitário da Universidade Federal de Sergipe

igor.bmf@gmail.com+55-79-991126209

Outcome results

None listed

Source: REBEC (via WHO ICTRP)